Orthopedic Growth Factor Market Size, Share, and Trends Analysis | Global | 2025-2031 | MedCore | Includes: Cervical Disc Degeneration Market, Tibial Fracture Market, and 2 more

  • Year: 2025
  • Scope: 10 Years
  • Region: Global
  • Published Date: 01/24/2025
  • Type: MedCore

Product Description

The global orthopedic growth factor market was valued at $1.05 billion in 2024. This is expected to increase over the forecast period at a CAGR of 2.2% to reach $1.2 billion.

The full report suite on the global orthopedic growth factor market categorizes growth factors into four indication types: cervical disc degeneration, tibial fractures, spine and ankle and hindfoot fusion.

This report includes data for 65 countries across 7 different regions. These regions are North America, Latin America, Western Europe, Central & Eastern Europe, Middle East, Asia-Pacific, and Africa.

DATA TYPES INCLUDED

  • Unit Sales, Average Selling Prices, Market Size & Growth Trends
  • Procedure Numbers
  • Market Drivers & Limiters
  • Market Forecasts Until 2031, and Historical Data to 2021
  • Recent Mergers & Acquisitions
  • Company Profiles and Product Portfolios
  • Leading Competitors

GLOBAL ORTHOPEDIC GROWTH FACTOR MARKET INSIGHTS

Global Orthopedic Growth Factor Market GrowthThe orthopedic growth factor market experienced a notable decline in sales due to the COVID-19 pandemic. The primary driver was the widespread cancellation and postponement of elective surgeries, which significantly disrupted the industry’s ecosystem. While this downturn was temporary, the impact in 2020 was substantial, with many companies incurring unprecedented losses. However, the market demonstrated resilience and managed to recover notably by 2022, returning to its trajectory of steady growth.

GLOBAL ORTHOPEDIC GROWTH FACTOR MARKET SHARE INSIGHTSTop Competitors in Growth Factor Market

  • Medtronic was the leader of the orthopedic growth factor market. Medtronic’s INFUSE® product remains the gold standard for spinal fusion therapies.
  • Cerapedics was the second-leading competitor in the orthopedic growth factor market in 2024. The company competes in the market with its i-Factor™, which recently received expanded FDA approval for single-level anterior cervical discectomy fusion (ACDF) with an allograft bone ring, or in conjunction with a polyetheretherketone (PEEK), titanium alloy or PEEK/titanium fusion interbody device to use in the cervical spine, and with supplemental anterior plate fixation.
  • Stryker held the third-leading position in the orthopedic growth factor market by offering the AUGMENT® product line, as the first and only U.S. Food and Drug Administration (FDA)-approved alternative to autograft in hindfoot and ankle arthrodesis.

GLOBAL ORTHOPEDIC GROWTH FACTOR MARKET SEGMENTATION SUMMARY

  • Cervical Disc Degeneration Market
  • Tibial Fracture Market
  • Spine
  • Ankle & Hindfoot Fusion

GLOBAL RESEARCH SCOPE

Report Attribute Details
Regions North America(Canada, United States)
Latin America(Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela)
Western Europe(Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom)
Central & Eastern Europe(Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine)
Middle East(Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates)
Asia Pacific(Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam)
Africa(Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda)
Base Year 2024
Forecast 2025-2031
Historical Data 2021-2023
Quantitative Coverage Procedure Numbers, Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices.
Qualitative Coverage COVID19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews.
Data Sources Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database.

 

FREE Sample Report

6.1 Executive Summary
6.1.1 Global Orthopedic Cell Therapy Market Overview
6.1.2 Competitive Analysis
6.1.3 Regions Included
6.2 Introduction
6.2.1 Platelet-Rich Plasma
6.2.2 Concentrated Bone Marrow Aspirate
6.3 Procedure Numbers
6.3.1 Total Orthopedic Cell Therapy Procedures
6.3.2 Platelet-Rich Plasma Procedures
6.3.3 Bone Marrow Aspirate Concentrate Procedures
6.4 Market Overview
6.4.1 By Segment
6.4.2 By Region
6.5 Market Analysis and Forecast
6.5.1 Platelet-Rich Plasma Market
6.5.2 Bone Marrow Aspirate Concentrate Market
6.6 Unit Analysis
6.6.1 Platelet-Rich Plasma Unit Analysis
6.6.1.1 Platelet-Rich Plasma Units Sold by Indication
6.6.2 Bone Marrow Aspirate Concentrate Unit Analysis
6.6.2.1 Bone Marrow Aspirate Concentrate Units Sold by Indication
6.7 Drivers and Limiters
6.7.1 Market Drivers
6.7.2 Market Limiters
6.8 Competitive Market Share Analysis
·         AbbVie ·         LCA Pharma
·         Acumed ·         LifeLink Tissue Bank
·         AlloSource ·         LifeNet Health
·         Alphatec Spine ·         Meda Pharma
·         Anika Therapeutics ·         Medtronic
·         Arthrex ·         MTF
·         B. Braun Melsungen ·         Novabone
·         Baxter ·         Nuo Therapeutics
·         Berkeley Advanced Biomaterials ·         Octane Medical
·         Biocell ·         Orthocell Ltd.
·         Biocomposites ·         OrthogenRx
·         Biogennix ·         Orthofix
·         Bioiberica ·         Osteogenics
·         Biomatlante ·         OsteoMed
·         Biotissue Technologies ·         Paragon 28
·         Bioventus ·         Plasmaconcept
·         Bonalive ·         PromoCell
·         Celling Biosciences ·         Rebone Biomaterials
·         Cerapedics ·         Recordati
·         Cingal ·         Regenexx
·         Croma-Pharma ·         Regenity Biosciences
·         CO.DON GmbH ·         RTI Surgical
·         CONMED ·         Sanofi
·         Curasan ·         Sartorius CellGenix GmbH
·         DCI Donor Services ·         Seikagaku
·         DePuy Synthes ·         Smith & Nephew
·         Documedica ·         Solvita
·         Elutia Inc. ·         Spinal Elements
·         Exactech ·         Stella Pharmaceuticals
·         Ferring Pharmaceuticals ·         Stryker
·         Fidia ·         Takara Bio
·         Finceramica ·         Tedec-Meiji
·         Geistlich ·         Terumo
·         Globus Medical/NuVasive ·         Teva Pharmaceutical
·         Hanmi Pharmaceutical ·         ThermoGenesis
·         Healiva ·         TRB Chemedica
·         IBSA Pharma ·         Viatris
·         Integra LifeSciences ·         Vericel
·         Isto Biologics ·         Vivex
·         Kolon Tissuegene ·         Xtant Medical
·         Kuros ·         Zimmer Biomet
Chart 6‑1: Orthopedic Cell Therapy Market, Global, 2024 & 2031
Chart 6‑2: Orthopedic Cell Therapy Procedures, Global, 2024
Chart 6‑3: Orthopedic Cell Therapy Procedures by Region, Global, 2021 – 2031
Chart 6‑4: Orthopedic Cell Therapy Market by Segment, Global, 2021 – 2031
Chart 6‑5: Orthopedic Cell Therapy Market by Region, Global, 2021 – 2031
Chart 6‑6: Leading Competitors, Orthopedic Cell Therapy Market, Global, 2024
Figure 6‑1: Orthopedic Cell Therapy Regions Covered, Global (1 of 2)
Figure 6‑2: Orthopedic Cell Therapy Regions Covered, Global (2 of 2)
Figure 6‑3: Orthopedic Cell Therapy Procedures by Segment, Global, 2021 – 2031
Figure 6‑4: Orthopedic Cell Therapy Procedures by Region, Global, 2021 – 2031
Figure 6‑5: Orthopedic Cell Therapy Procedures by Country, North America, 2021– 2031
Figure 6‑6: Orthopedic Cell Therapy Procedures by Country, Latin America, 2021 – 2031 (1 of 2)
Figure 6‑7: Orthopedic Cell Therapy Procedures by Country, Latin America, 2021 – 2031 (2 of 2)
Figure 6‑8: Orthopedic Cell Therapy Procedures by Country, Western Europe, 2021 – 2031
Figure 6‑9: Orthopedic Cell Therapy Procedures by Country, Central & Eastern Europe, 2021 – 2031 (1 of 2)
Figure 6‑10: Orthopedic Cell Therapy Procedures by Country, Central & Eastern Europe, 2021 – 2031 (2 of 2)
Figure 6‑11: Orthopedic Cell Therapy Procedures by Country, Middle East, 2021 – 2031
Figure 6‑12: Orthopedic Cell Therapy Procedures by Country, Asia-Pacific, 2021 – 2031 (1 of 3)
Figure 6‑13: Orthopedic Cell Therapy Procedures by Country, Asia-Pacific, 2021 – 2031 (2 of 3)
Figure 6‑14: Orthopedic Cell Therapy Procedures by Country, Asia-Pacific, 2021 – 2031 (3 of 3)
Figure 6‑15: Orthopedic Cell Therapy Procedures by Country, Africa, 2021 – 2031
Figure 6‑16: Orthopedic Platelet-Rich-Plasma Procedures by Region, Global, 2021 – 2031
Figure 6‑17: Orthopedic Platelet-Rich-Plasma Procedures by Country, North America, 2021 – 2031
Figure 6‑18: Orthopedic Platelet-Rich-Plasma Procedures by Country, Latin America, 2021 – 2031 (1 of 2)
Figure 6‑19: Orthopedic Platelet-Rich-Plasma Procedures by Country, Latin America, 2021 – 2031 (2 of 2)
Figure 6‑20: Orthopedic Platelet-Rich-Plasma Procedures by Country, Western Europe, 2021 – 2031
Figure 6‑21: Orthopedic Platelet-Rich-Plasma Procedures by Country, Central & Eastern Europe, 2021 – 2031 (1 of 2)
Figure 6‑22: Orthopedic Platelet-Rich-Plasma Procedures by Country, Central & Eastern Europe, 2021 – 2031 (2 of 2)
Figure 6‑23: Orthopedic Platelet-Rich-Plasma Procedures by Country, Middle East, 2021 – 2031
Figure 6‑24: Orthopedic Platelet-Rich-Plasma Procedures by Country, Asia-Pacific, 2021 – 2031 (1 of 3)
Figure 6‑25: Orthopedic Platelet-Rich-Plasma Procedures by Country, Asia-Pacific, 2021 – 2031 (2 of 3)
Figure 6‑26: Orthopedic Platelet-Rich-Plasma Procedures by Country, Asia-Pacific, 2021 – 2031 (3 of 3)
Figure 6‑27: Orthopedic Platelet-Rich-Plasma Procedures by Country, Africa, 2021 – 2031
Figure 6‑28: Orthopedic Bone Marrow Aspirate Concentrate Procedures by Region, Global, 2021 – 2031
Figure 6‑29: Orthopedic Bone Marrow Aspirate Concentrate Procedures by Country, North America, 2021 – 2031
Figure 6‑30: Orthopedic Bone Marrow Aspirate Concentrate Procedures by Country, Latin America, 2021 – 2031 (1 of 2)
Figure 6‑31: Orthopedic Bone Marrow Aspirate Concentrate Procedures by Country, Latin America, 2021 – 2031 (2 of 2)
Figure 6‑32: Orthopedic Bone Marrow Aspirate Concentrate Procedures by Country, Western Europe, 2021 – 2031
Figure 6‑33: Orthopedic Bone Marrow Aspirate Concentrate Procedures by Country, Central & Eastern Europe, 2021 – 2031 (1 of 2)
Figure 6‑34: Orthopedic Bone Marrow Aspirate Concentrate Procedures by Country, Central & Eastern Europe, 2021 – 2031 (2 of 2)
Figure 6‑35: Orthopedic Bone Marrow Aspirate Concentrate Procedures by Country, Middle East, 2021 – 2031
Figure 6‑36: Orthopedic Bone Marrow Aspirate Concentrate Procedures by Country, Asia-Pacific, 2021 – 2031 (1 of 3)
Figure 6‑37: Orthopedic Bone Marrow Aspirate Concentrate Procedures by Country, Asia-Pacific, 2021 – 2031 (2 of 3)
Figure 6‑38: Orthopedic Bone Marrow Aspirate Concentrate Procedures by Country, Asia-Pacific, 2021 – 2031 (3 of 3)
Figure 6‑39: Orthopedic Bone Marrow Aspirate Concentrate Procedures by Country, Africa, 2021 – 2031
Figure 6‑40: Orthopedic Cell Therapy Market by Segment, Global, 2021 – 2031 (US$M)
Figure 6‑41: Orthopedic Cell Therapy Market by Region, Global, 2021 – 2031 (US$M)
Figure 6‑42: Platelet-Rich Plasma Market, Global, 2021 – 2031
Figure 6‑43: Units Sold by Region, Platelet-Rich Plasma Market, Global, 2021 – 2031
Figure 6‑44: Average Selling Price by Region, Platelet-Rich Plasma Market, Global, 2021 – 2031 (US$)
Figure 6‑45: Market Value by Region, Platelet-Rich Plasma Market, Global, 2021 – 2031 (US$M)
Figure 6‑46: Bone Marrow Aspirate Concentrate Market, Global, 2021 – 2031
Figure 6‑47: Units Sold by Region, Bone Marrow Aspirate Concentrate Market, Global, 2021 – 2031
Figure 6‑48: Average Selling Price by Region, Bone Marrow Aspirate Concentrate Market, Global, 2021 – 2031 (US$)
Figure 6‑49: Market Value by Region, Bone Marrow Aspirate Concentrate Market, Global, 2021 – 2031 (US$M)
Figure 6‑50: Platelet-Rich Plasma Units Sold by Indication, Global, 2021 – 2031
Figure 6‑51: Bone Marrow Aspirate Concentrate Units Sold by Indication, Global, 2021 – 2031
Figure 6‑52: Leading Competitors, Orthopedic Cell Therapy Market, Global, 2024

iData’s 9-Step Research Methodology

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology

Explore Options

Report Summary

FREE

Select License Type

  • 2025
  • 10 Years
  • Global
  • 01/24/2025
  • MedCore
0
    0
    Your Cart
    Your cart is emptyReturn to Report Library